Oncology-focused biopharma Immuneering Corp jumps in market debut

Hanall Biopharma

30/07/2021 16:50

** Shares of biopharma co  IMRX.O  open 30% above offer
price in Nasdaq debut
    ** Stock opens at $19/shr, up from $15/shr IPO price
    ** On Thursday, co raised $112.5 mln in its upsized IPO,
selling 7.5 mln shares  urn:newsml:reuters.com:*:nGNX5YpxzZ
    ** Co had earlier aimed to sell 7 mln shares at a price
between $14 and $16 each
    ** IMRX, which was founded in 2008, focuses on treatments
for cancer and neurological diseases 
    ** Co says will use proceeds to advance development of lead
product candidate IMM-1-104 and for other programs
    ** Morgan Stanley, Jefferies, Cowen and Guggenheim
Securities were the underwriters

 (Reporting by Niket Nishant in Bengaluru)
 ((Niket.Nishant@thomsonreuters.com;))